In brief
The Trump administration has announced a new agreement resulting in reduced prices for 15 popular prescription drugs used by Medicare beneficiaries, expected to save billions in taxpayer dollars. Health Secretary Robert F. Kennedy Jr. emphasized the commitment to improving healthcare affordability for seniors. While the finalized prices depend on individual plans, the reductions aim to provide significant financial relief. The announcement follows negotiations under a 2022 law that enables Medicare to negotiate drug prices, and more rounds are planned for next year, indicating an ongoing commitment to tackling healthcare costs.
NEW YORK (AP) — Pharmaceutical companies have agreed to cut Medicare prices for 15 prescription drugs, leading to anticipated savings for taxpayers and older adults, according to the Trump administration.
Health Secretary Robert F. Kennedy Jr. highlighted these negotiations as part of the administration’s ongoing initiatives to enhance affordability for Americans. The drug negotiation program, which was originally mandated under President Joe Biden, aims to make vital medications more accessible for seniors.
“President Trump directed us to prioritize lowering health care costs. We are committed to ensuring that healthcare remains affordable for the American people,” Kennedy stated.
This announcement marks the end of a second round of negotiations under a 2022 law that allows Medicare to negotiate pricing on high-demand and expensive medications, bringing the total negotiated drug prices to 25. The newly agreed prices are set to take effect in 2027.
Negotiated Prices for Essential Medications
The medications affected include popular GLP-1 weight-loss and diabetes treatments such as Ozempic, Rybelsus, and Wegovy, alongside other essential drugs for conditions like asthma and cancer.
This round of negotiations is expected to yield about $8.5 billion in savings if applied retroactively to the previous year. However, individual beneficiaries' exact out-of-pocket expenses remain uncertain due to variables in their insurance plans. A new rule will also cap individual out-of-pocket costs at $2,000, providing additional financial relief.
Ongoing Changes and Controversies
Despite the achievements in drug pricing, the Trump administration continues facing pushback from pharmaceutical companies, which have raised concerns over the impact of these negotiations on innovation and overall market competition.
As Medicare moves forward with negotiations for an additional 15 drugs next year, including those administered by physicians, it remains clear that the administration is committed to making medications more affordable for the American public.
